Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
- Details
- Category: Novartis

Merck Submits Application for Cladribine Tablets
- Details
- Category: Merck Group

The Lilly TB Drug Discovery Initiative Announces New Collaborator
- Details
- Category: Eli Lilly and Company

Abbott to Acquire Solvay Pharmaceuticals Business
- Details
- Category: Abbott

Novartis bronchodilator QAB149 recommended for approval in European Union
- Details
- Category: Novartis

Results from Abbott's PROSPECT Study Provide New Insight
- Details
- Category: Abbott

Herceptin provides impressive survival benefit for patients with high levels of HER2
- Details
- Category: Roche

More Pharma News ...
- Results of ADAGIO study with Azilect® in Parkinson's disease published
- Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival
- Analysis of BRAIN study shows that patients may have a stabilisation or improvement
- Denosumab Demonstrates Superiority Over Zometa(R)
- Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim
- Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
- Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress